Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The National Institute of Neurological Disorders and Stroke, National Institutes of Health, and Lixte Biotechnology Holdings have extended co-operative research and development agreement to develop drugs for the treatment of brain cancers.
Subscribe to our email newsletter
The co-operative research and development agreement, initiated in March 2006, was extended through September 2009.
John Kovach, president and CEO of Lixte, said: “The scientific interaction with the research team at the molecular pathogenesis unit, surgical neurology branch, National Institute of Neurological Disorders and Stroke (NINDS), has been highly productive and is a good example of how government and private sector scientific organizations may accelerate the drug development process.”